All News about Enlivex Therapeutics Ltd
![](https://www.globenewswire.com/Content/Images/intrado.png)
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://ml.globenewswire.com/media/20c4355c-ab8b-45bd-b7a5-2c2cfa189c38/small/untitled-jpg.jpg)
![](https://ml.globenewswire.com/media/20c4355c-ab8b-45bd-b7a5-2c2cfa189c38/small/untitled-jpg.jpg)
![](https://ml.globenewswire.com/media/20c4355c-ab8b-45bd-b7a5-2c2cfa189c38/small/untitled-jpg.jpg)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](/next-assets/images/schema-image-default.png)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://cdn.benzinga.com/files/images/story/2024/04/12/tesla-logo1.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/04/11/crude_oil_6-_logo.jpg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://cdn.benzinga.com/files/images/story/2024/04/11/fastenal_-_logo.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/04/11/image21.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/04/11/image10_0.jpg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://edge-cdn.isdr.io/accesswire/Accesswire_256x256.png )
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
Enlivex Therapeutics Ltd. (NASDAQ: ENLV) Leading the Way in Tuesday Trading Based on Percentage Gain
January 02, 2024
Exposures
COVID-19
![](https://ml.globenewswire.com/media/5656273e-e391-430c-b120-0d021f2e70b8/small/logo-png.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.